Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PERFUSE - One-year Persistence to Treatment of Patients Receiving Flixabi or Imraldi: a French Cohort Study

Trial Profile

PERFUSE - One-year Persistence to Treatment of Patients Receiving Flixabi or Imraldi: a French Cohort Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Infliximab (Primary)
  • Indications Ankylosing spondylitis; Crohn's disease; Inflammatory bowel diseases; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms PERFUSE
  • Sponsors Biogen
  • Most Recent Events

    • 01 Apr 2023 Results (n=126 pediatric IBD patients cohort) assessing response to treatment and persistence on SB2 for up to 12 months in pediatric IBD patients published in the Journal of Pediatric Gastroenterology and Nutrition
    • 17 Oct 2022 Status changed from active, no longer recruiting to completed.
    • 06 Aug 2021 Status changed from recruiting to active, no longer recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top